Abstract
Background: Psoriasis is a chronic inflammatory disease that is often treated with biologic agents. The association between current biologic agents used for psoriasis and melanoma risk is unclear. Methods We performed a retrospective analyses of the Australasian Psoriasis Registry (APR) dataset and reviewed the published safety data to look for any safety signal when it comes to biologics for psoriasis and melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
